In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM). He then reviews the diagnosis and management of Kawasaki Disease. Finally, Dr. Eagle ...

A State-of-the-Art review published in JACC outlines the range of potential opportunities for the incorporation of artificial intelligence (AI) in the design and implementation of cardiovascular ...

Quantitative coronary plaque analysis (QCPA) is an emerging tool that allows noninvasive quantification and characterization of coronary atherosclerosis on the basis of coronary computed tomography ...

There was a genetic distinction identified among development of aortic stenosis (AS) and elevated serum phosphate levels contributed to risk. The genetic correlation among coronary artery disease and ...

Sudden cardiac death (SCD) in obesity is the focus of a JACC: State-of-the-Art review of the mechanisms as well as current evidence for its management, gaps in knowledge and future research, published ...

Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack ...

Disparities in health care disproportionally impact under-resourced and minority communities resulting in excess mortality and morbidity. Decreasing and eliminating these disparities will improve ...

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs ...

American Society of Echocardiography (ASE) guidelines for echocardiographic evaluation of aortic regurgitation (AR) were found to “display very good performance” in detecting significant AR, according ...

The U.S. Food and Drug Administration (FDA) posted a letter to health care providers on Nov. 15, announcing that Getinge/Maquet has issued an Urgent Medical Device Removal notice warning against use ...

This handbook is intended for all of those involved with treating patients with structural heart disease. In developing this resource, our goal was to provide a single source of introductory ...

The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...